Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-12-14
- Target Recruit Count
- 16
- Registration Number
- NCT00000875
- Locations
- 🇺🇸
The Ctr For Blood Research Inc, Boston, Massachusetts, United States
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-07-29
- Target Recruit Count
- 300
- Registration Number
- NCT00000882
- Locations
- 🇺🇸
State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States
🇺🇸Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT00002035
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Albany Med College / AIDS Treatment Ctr, Albany, New York, United States
🇺🇸Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 18
- Registration Number
- NCT00000986
- Locations
- 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 280
- Registration Number
- NCT00000831
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States
🇺🇸Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 1500
- Registration Number
- NCT00006396
- Locations
- 🇺🇸
Missie Allen, Research Triangle Park, North Carolina, United States
Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 256
- Registration Number
- NCT00000838
- Locations
- 🇺🇸
Stanford CRS, Palo Alto, California, United States
🇺🇸Santa Clara Valley Med. Ctr., San Jose, California, United States
🇺🇸San Mateo County AIDS Program, San Mateo, California, United States
A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000995
- Locations
- 🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Rochester Medical Center, Rochester, New York, United States
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 400
- Registration Number
- NCT00000712
- Locations
- 🇺🇸
Massachusetts General Hospital ACTG CRS, Worcester, Massachusetts, United States
🇺🇸Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States
🇺🇸Bmc Actg Crs, Boston, Massachusetts, United States
Granulocyte-Macrophage Colony-Stimulating Factor and Zidovudine: A Phase I Study of Concurrent Administration in Patients With AIDS and Severe ARC
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 60
- Registration Number
- NCT00000711
- Locations
- 🇺🇸
SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.